Skip to main content
SpringerLink
Log in

Chronic Kidney Disease: Cardiovascular Complications

  • Chapter
  • First Online:
Primer on Nephrology

  • 2039 Accesses

Abstract

Diseases of the cardiovascular system, presenting as sudden death, myocardial infarction, stroke, heart failure and gangrene, are particularly common in patients with chronic kidney disease (CKD) and substantially limit quality of life and life expectancy (McCullough PA, Li S, Jurkovitz CT, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156:277–83 and Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81). Whether established treatment strategies that have proven to be successful in other high-risk groups have similar benefits in the context of CKD is not clear, partly because these patients are often excluded from large clinical trials. Furthermore, the underlying pathophysiology of cardiovascular disease may change as kidney function declines, so additional or alternative approaches to management may be appropriate. The management of cardiovascular disease (CVD) remains a challenge for health-care professionals responsible for the care of patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  CAS  Google Scholar 

  2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799–805.

    Article  CAS  Google Scholar 

  3. Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51:S13–20.

    Article  CAS  Google Scholar 

  4. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35:S117–31.

    Article  CAS  Google Scholar 

  5. Ronco C, McCullough PA, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Herart J. 2010;31:703–11.

    Article  Google Scholar 

  6. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388:276–84.

    Article  Google Scholar 

  7. Park M, Hsu CY, Li Y, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012;23:1725–34.

    Article  CAS  Google Scholar 

  8. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008;3:19–26.

    Article  Google Scholar 

  9. Defilippi C, Seliger SL, Kelley W, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem. 2012;58:1342–51.

    Article  CAS  Google Scholar 

  10. Lippi G, Tessitore N, Montagnana M, et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008;132:72–6.

    Article  CAS  Google Scholar 

  11. Bergeron S, Hillis GS, Haugen EN, et al. Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease. Am Heart J. 2007;153:385–91.

    Article  Google Scholar 

  12. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120:851–8.

    Article  CAS  Google Scholar 

  13. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104:1647–53.

    Article  Google Scholar 

  14. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005;149:512–9.

    Article  Google Scholar 

  15. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156:445–59.

    Article  Google Scholar 

  16. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357–65.

    Article  CAS  Google Scholar 

  17. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Eur Heart J. 2018;39(24):2314–25.

    Article  CAS  Google Scholar 

  18. Garlo KG, Steele DJR, Nigwekar SU, Chan KE. Demystifying the benefits and harms of anticoagulation for atrial fibrillation in chronic kidney disease. Clin J Am Soc Nephrol. 2019;14:125–36.

    Article  CAS  Google Scholar 

  19. Ullal AJ, Kaiser DW, Fan J, et al. Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease. J Cardiovasc Electrophysiol. 2017;28(1):39–48.

    Article  Google Scholar 

  20. Walters RJ, Fox NC, Crum WR, et al. Haemodialysis and cerebral oedema. Nephron. 2001;87:143–7.

    Article  CAS  Google Scholar 

  21. Plantinga LC, Fink NE, Coresh J, et al. Peripheral vascular disease-related procedures in dialysis patients: predictors and prognosis. Clin J Am Soc Nephrol. 2009;4:1637–45.

    Article  Google Scholar 

  22. Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive blood pressure control in CKD. J Am Soc Nephrol. 2019;30(8):1523–33.

    Article  Google Scholar 

  23. Kusaba T, Mori Y, Masami O, et al. Sodium restriction improves the gustatory threshold for salty taste in patients with chronic kidney disease. Kidney Int. 2009;76:638–43.

    Article  CAS  Google Scholar 

  24. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.

    Article  Google Scholar 

  25. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19:999–1007.

    Article  CAS  Google Scholar 

  26. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  Google Scholar 

  27. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  CAS  Google Scholar 

  28. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  CAS  Google Scholar 

  29. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–36.

    Article  CAS  Google Scholar 

  30. Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961–70.

    Article  CAS  Google Scholar 

  31. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

    Article  Google Scholar 

  32. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial. Circulation. 2019; https://doi.org/10.1161/CIRCULATIONAHA.119.042007. [Epub ahead of print].

  33. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956–65.

    Article  CAS  Google Scholar 

  34. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  Google Scholar 

  35. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662–8.

    Article  CAS  Google Scholar 

  36. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117:224–30.

    Article  Google Scholar 

  37. EVOLVE trail investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–94.

    Article  Google Scholar 

  38. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–41.

    Article  CAS  Google Scholar 

  39. Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ. 2012;344:e3533.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Renal Medicine, UCL Medical School, Royal Free Campus, London, UK

    Katharine Pates, Ben Caplin & David C. Wheeler

Authors
  1. Katharine Pates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ben Caplin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David C. Wheeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Wheeler .

Editor information

Editors and Affiliations

  1. Department of Renal Medicine, UCL, London, UK

    Mark Harber

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pates, K., Caplin, B., Wheeler, D.C. (2022). Chronic Kidney Disease: Cardiovascular Complications. In: Harber, M. (eds) Primer on Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-76419-7_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-76419-7_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-76418-0

  • Online ISBN: 978-3-030-76419-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation